On August 21, Bristol-Myers Squibb fell 3.03% in regular trading, trading at $65.565/share, with turnover of $4.26 billion. The decline came as the broader pharmaceutical sector experienced selling pressure across major names.

The pharmaceutical industry faced headwinds during the session, with heavyweight stocks declining in tandem. Eli Lilly fell 2.68%, Merck dropped 2.02%, and Johnson & Johnson slid 1.93%. The sector-wide weakness weighed on Bristol-Myers Squibb despite recent positive developments including the FDA accelerated approval of its Celmod therapy Zenbexus for multiple myeloma on August 14, and its newly announced AI collaboration with Chai Discovery for antibody development. The stock had gained 3.11% in the prior session, suggesting some degree of profit-taking may also be contributing to the pullback.

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering and developing innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience therapeutic areas.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)